Article Sidebar

PDF
Date Published: 13/01/2022
Abstract Views: 544
Views PDF: 264
DOI: https://doi.org/10.51298/vmj.v509i2.1857
Issue
Vol. 509 No. 2 (2021)
Section
Các bài báo
How to Cite
Tiến Quang, N. ., Huyền Nga, Đỗ ., & Thanh Tùng, N. . (2022). ASSESSMENT THE EFFECTIVENESS OF RITUXIMAB REGIMENS IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA AT K HOSPITAL. Vietnam Medical Journal, 509(2). https://doi.org/10.51298/vmj.v509i2.1857

ASSESSMENT THE EFFECTIVENESS OF RITUXIMAB REGIMENS IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA AT K HOSPITAL

Nguyễn Tiến Quang1,, Đỗ Huyền Nga1, Nguyễn Thanh Tùng1
1 K Hospital

Main Article Content

Abstract

Objectives: To evaluate the effectiveness of a rituximab regimens in the first line treatment of follicular lymphoma at K hospital. Subjects and methods: A prospective descriptive study conducted on 24 follicular lymphoma patients treated with rituximab regimens from May 2019 to October 2021. Results: The average age of the patients was 59.71, the sex ratio male/female was 2.0, almost patients were hospitalized because of lymphadenopathy 70.7%; almost patient have stage 3 accounted for 62%; The overall response rate of RB group was 100%. The overall response rate of RCHOP/RCVP group was 87.4%. The toxicity rate of RCHOP/RCVP group was 75% while the toxicity rate of the RB group was 25%. Conclusion: The RB regimen has a higher response rate and safety than the RCHOP/RCVP regimen in the first line treatment of follicular lymphoma.

Article Details

Keywords

follicular lymphoma (FL)

References

1. Trần Văn Thuấn. Hướng dẫn chẩn đoán và điều trị bệnh ung thư thường gặp. Nhà xuất bản Y học. 2019:5-24.
2. Arnold S Freedman. Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma. Uptodate. 2021:1-14.
3. Andrew D.Z. NCCN Clinical practice guidelines in Oncology - B-Cell lymphomas. NCCN. 2020:12-65.
4. Mondello P. et al. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. Ann

Hematol. 2016;95(7):1107-1114.
5. Takashi Watanabe. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol. 2018:520-531.
6. Ganguly Siddhartha, Patel Vijay. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2009:14-19.
7. Mondello P. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. Ann Hematol. 2016;(7)(95):1107-1114.
8. Flinn I. W. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood Journal. 2014;123(19):2944-2952.